NCT01359228

Rifaximin Treatment of Papulopustular Rosacea

Rifaximin Treatment of Papulopustular Rosacea: Double- Blinded, Placebo-Controlled, Crossover Study

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of California, San Francisco · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effects of rifaximin on skin symptoms in patients with rosacea by double-blinded, placebo-controlled, crossover study.

Detailed description

100 patients will be randomized into two groups. Group A will receive one rifaximin 550 mg tablet three times a day (1650 mg/day) for 14 days, and after a 4-week washout period, receive one placebo tablet three times a day for 14 days. Group B will receive placebo first, and then rifaximin with the same dosage schedule to Group A. Assessments will be performed before application and 4 weeks after the last dosage, for both of rifaximin and placebo.

Conditions

• Rosacea

Interventions

Type	Name	Description
DRUG	Rifaximin (XIFAXAN)	Rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days
DRUG	Placebo	Placebo 1 tablet three times a day for 14 days.

Timeline

• Start date: 2013-04-01
• Primary completion: 2014-06-01
• Completion: 2014-12-01
• First posted: 2011-05-24
• Last updated: 2014-04-28

Locations

1 site across 1 country: United States